RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and intermediates business of Raghava Life Sciences for up to Rs 135 crore is not, by pharmaceutical M&A standards, a mega-deal.

But it is strategically revealing.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Free Membership Required

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

Topics

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

Related Articles

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Company

Headlines

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Newsletter